Piramal Pharma Q2 Results: Piramal Pharma reported a significant increase in its consolidated net profit, which surged more than four times to Rs 23 crore for the quarter ending September, compared to Rs 5 crore during the same period last year. The company’s revenue from operations also rose to Rs 2,242 crore, up from Rs 1,911 crore in the previous year.
Also Read: Rupee Recovers Marginally From Historic Low: Opens at 84.069 Against Dollar!
Chairperson Nandini Piramal highlighted that the company is maintaining strong revenue growth, coupled with year-on-year EBITDA margin expansion. This growth is largely attributed to a robust performance in the Contract Development and Manufacturing Organization (CDMO) segment, which has seen increased innovation-related projects and revenues from on-patent products.
To sustain this upward trajectory and meet rising demand for sterile fill-finish capabilities, Piramal Pharma has announced an ambitious USD 80 million expansion plan at its Lexington facility. This expansion is expected to be completed by the end of fiscal year 2027.
In the Complex Hospital Generics (CHG) sector, the company is observing steady growth in the volume of inhalation anesthesia products in both the U.S. and emerging markets. Furthermore, capacity expansions at its facilities in Dahej, Gujarat, and Digwal, Telangana, are underway to seize opportunities in the Rest of the World (RoW) markets.
Also Read: Q2 Results Today: 50+ Major Companies to Announce Q2 Performance on October 24; check full list
Piramal Pharma is also focusing on portfolio diversification by developing a range of differentiated and specialty products aimed at fostering long-term growth. In its India Consumer Healthcare (ICH) segment, robust growth in power brands and e-commerce sales has been noted. The company plans to enhance its market reach by transitioning to an omnichannel consumer healthcare model from a pharmacy-focused approach.
